Journal
NATURE BIOTECHNOLOGY
Volume 27, Issue 1, Pages 59-65Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.1515
Keywords
-
Categories
Funding
- (NIH)/National Eye Institute [R21EY018491]
- NIH/ National Institute of Neurological Disorders and Stroke (NINDS) [R21NS064328]
- NATIONAL EYE INSTITUTE [R21EY018491] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064492, R21NS064328] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Delivery of genes to the brain and spinal cord across the blood-brain barrier (BBB) has not yet been achieved. Here we show that adeno-associated virus (AAV) 9 injected intravenously bypasses the BBB and efficiently targets cells of the central nervous system (CNS). Injection of AAV9-GFP into neonatal mice through the facial vein results in extensive transduction of dorsal root ganglia and motor neurons throughout the spinal cord and widespread transduction of neurons throughout the brain, including the neocortex, hippocampus and cerebellum. In adult mice, tail vein injection of AAV9-GFP leads to robust transduction of astrocytes throughout the entire CNS, with limited neuronal transduction. This approach may enable the development of gene therapies for a range of neurodegenerative diseases, such as spinal muscular atrophy, through targeting of motor neurons, and amyotrophic lateral sclerosis, through targeting of astrocytes. It may also be useful for rapid postnatal genetic manipulations in basic neuroscience studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available